Navigation Links
High dose UDCA therapy does not improve overall liver histology in obesity related hepatitis
Date:4/16/2010

Vienna, Austria, Friday 16 April: Results of a German study presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid (UDCA) is no more effective than placebo in the treatment of non-alcoholic steatohepatitis (NASH), the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver .

NASH is a serious development of non-alcoholic fatty liver disease (NAFLD), the most common persistent liver disorder in western countries and for which there is no proven medical therapy. Results from this study show that high dose UDCA a naturally occurring bile acid, historically used to treat gallstones is not superior to placebo therapy. Moderate histological and biochemical improvement was only observed in a subgroup of mildly overweight male patients.

Commenting on the study, Professor Fabio Marra of the EASL scientific committee said: "The use of UDCA is still considered controversial in non-alcoholic hepatitis, although previous research has suggested that the treatment may have some beneficial effects. The results of this study indicate that high dose UDCA is not superior to placebo except in a small subset of individuals. Nevertheless, the results do provide some interesting clinical pointers for clinicians in this field."

In the study, patients with histologically proven NASH (n=186, 147 of whom proceeded to treatment) were organised according to gender, body weight, liver biochemistry and histology and were randomised to receive either 23-28mg/kg/d UDCA or placebo for a period of 18 months.

Pre- and post-treatment liver biopsies from 139 patients were analysed, the primary evaluation criteria was an improvement in liver histology and secondary criteria were improvements in NASH-associated histological findings and liver function
'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Seattle Facial Plastic Surgeon Among First In The Nation To Offer Ultherapy™
2. Cell Therapy Group Announces Expansion of Consultants Roster in Regenerative Medicine
3. Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
4. Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer
5. California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS
6. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
7. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
8. Progenitor Cell Therapy Expands Manufacturing Operations
9. Stroke Therapy with Corkscrew Device Most Beneficial, Study Suggests
10. Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries
11. Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
(Date:10/19/2014)... 19, 2014 The Latin American hardware ... in Latin America with analysis and forecast of revenue. ... and is expected to reach $2,366.8 million by 2018, ... , Browse through the TOC of the Latin American ... the in-depth analysis provided. It also provides a glimpse ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines and ... of revenue. The Automatic patient billing market in Asia ... 2018, at a developing CAGR of 7.2% from 2013 ... Asian Automatic patient billing market, to get an idea ... glimpse of the segmentation of this market in the ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... YORK, Aug. 24 The DNA sequencing equipment ... and 2012, spiraling upward from,$335 million to $528 ... Sequencing Equipment and Service Markets, a new report ... been relatively stable for the last,several years, with ...
... Conference Call Originally Scheduled for 9:00 a.m. Eastern Time ... Be Rescheduled After Private Placement Closes -, FREMONT, ... (Nasdaq: CIPH ), today announced that it,has entered ... with a group of existing and new investors. Under ...
... DIEGO, Aug. 23 eBioscience Corporation announced,the appointment ... eBioscience, effective,immediately. Dr. Nelson comes to eBioscience from ... Development. Dr. Nelson will assume the role ... as President during a transition period. Nelson will,also ...
Cached Biology Technology:DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop 2Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock 2Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock 3Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc. 2
(Date:10/18/2014)... 2,000 patients referred for evaluation of suspected genetic ... for 25 percent, including detection of a number ... to disease, according to a study appearing in ... to coincide with the American Society of Human ... exons or coding regions of thousands of genes ...
(Date:10/17/2014)... release is available in German . ... a very few drugs. When treating overdoses, doctors are often ... especially difficult if there is a combination of drugs involved. ... and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux ... to find an answer to this question. "The task was ...
(Date:10/16/2014)... are anything but sustainable: environmental damage to soil ... increasingly evident. Despite their disadvantages, however, monocultures remain ... the sole possibility of achieving higher yields in ... an ecology professor at the University of Zurich, ... forestry. After all, a new study carried out ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... NEWTOWN SQUARE, Pennsylvania, September 27, 2011 An ... U.S. Forest Service,s Forest Inventory and Analysis (FIA) program ... eastern United States is increasing despite infestations of hemlock ... The information comes from an e-Science Update co-authored by ...
... ROUGE A research team led by LSU Associate Professors ... the results of a combined field and laboratory study showing ... living in Louisiana marshes. , The study, funded ... the Gulf of Mexico Research Initiative is being published in ...
... ... Presidential Early Career Award for Scientists and Engineers (PECASE). The award ... scientists and engineers in the early stages of their careers. ... significant award," said Jane Lubchenco, Ph.D., under secretary of commerce for ...
Cached Biology News:US Forest Service study finds hemlock still abundant despite adelgid infestation 2LSU researchers find impact of oil spill in marsh fish species 2President to honor high achieving, early career NOAA scientists 2
Request Info...
... Cell Expansion Kit - Neurosphere is a system ... cell expansion as neurospheres in a serum free ... Plus Media Supplement, which has been optimized for ... al . (1996) Genes & Development 10 ...
... Source: Calf thymus Description: Topoisomerase I ... a transient breakage and rejoining of phosphodiester bonds ... allows molecules to be differentiated by a single ... I is active in the absence of Mn ...
... Topo I, Wild Type ... 1 mM DTT, 200 µM EDTA, 20% glycerol, ... I (Topo I) is a monomeric protein of ... It catalyzes the relaxation of both positive and ...
Biology Products: